Brokerage Firm Rating on Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX) : 14 analysts are covering Becton Dickinson and Company (BDX) and their average rating on the stock is 1.57, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Becton Dickinson and Company (BDX) : 12 Wall Street analysts covering Becton Dickinson and Company (BDX) believe that the average level the stock could reach for the short term is $184.58. The maximum price target given is $200 and the minimum target for short term is around $169, hence the standard deviation is calculated at $9.4.


For the current week, the company shares have a recommendation consensus of Buy. Becton Dickinson and Company (NYSE:BDX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $175.00 and $174.09 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $177.27. The buying momentum continued till the end and the stock did not give up its gains. It closed at $176.71, notching a gain of 0.99% for the day. The total traded volume was 936,744 . The stock had closed at $174.97 on the previous day.

In a related news, Gallagher John E, officer (VP, Corp Finance and Treasurer) of Becton Dickinson & Co, unloaded 1,931 shares at an average price of $169.87 on June 13, 2016. The total amount of the transaction was worth $328,019, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.